|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
 |
|
|
Radium-223 in Clinical Practice
|
Phillip J. Koo, MD, FACS
Phillip Koo joins Neal Shore to discuss radium-223 for treating men with metastatic castration-resistant prostate cancer. Radium-223 has improved overall survival and reduced symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer and bone metastases (ALSYMPCA trial).
|
|
|
|
|
|
|
|
|
 |
|
|
The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer
|
Fred Saad, MD, FRCS
Fred Saad and Alicia Morgans have a discussion on bone health in prostate cancer patients, an issue for men with advanced prostate cancer and an important topic to keep at the forefront of care. Even though men are living longer, bone metastases increases mortality and impair a person's independence.
|
|
|
|
|
|
|
|
|
 |
|
|
Anti-resorptive Therapy to Reduce Skeletal-Related Events Risk in Men with Bone-Metastatic CRPC Presentation
|
|
Chris Parker, MD, FRCR, MRCP
|
| Chris Parker presents on the utilization of antiresorptive therapy to reduce skeletal-related events risk in men with bone metastatic castration-resistant prostate cancer (mCRPC). His presentation was part of a debate at the Advanced Prostate Cancer Consensus Conference (APCCC 2019).
|
|
|
|
|
|
|
|
|
|
 |
|
|
Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy
|
|
Noel Clarke MBBS, FRCS, ChM
|
| Noel Clarke a Consultant Urologist at Salford Royal Hospital presents in opposition of treating all patients with bone-targeted therapy during his portion of the debate on bone-targeted therapy with zoledronate or denosumab.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PUBLICATIONS FOCUSING ON UROLOGIC CANCER TREATMENTS THROUGH ORIGINAL MANUSCRIPTS
|
|
|
|
| EVERDAY UROLOGY: VOLUME 4, ISSUE 2 |
 |
|
| Optimizing Bone Health in Prostate Cancer
|
| Fred Saad, MD, FRCS
|
| Protecting and improving bone health is critical when managing all stages of prostate cancer. Androgen deprivation therapy (ADT) accelerates bone resorption, which compromises bone mass and integrity starting early in treatment. Metastatic prostate cancer is associated with a marked increase in risk of skeletal events (fracture, spinal cord compression, and bone surgery or radiotherapy) associated with both bone metastases and treatment-induced bone loss.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECENT DATA FROM CONFERENCES WORLDWIDE |
|
|
|
| “M1|RT Comparison” in STAMPEDE, Benefit of Prostate Radiotherapy for Patients with Lymph Node Only or Bone Metastasis and No Visceral Metastases
|
| Syed Adnan Ali, MBBS
|
| In this abstract, STAMPEDE investigators sought to better understand which patients benefit from the addition of radiation therapy (RT) to standard of care (SOC) treatment for newly diagnosed metastatic hormone sensitive prostate cancer. Specifically, they aimed to answer the following questions: 1) Does prostate RT + SOC benefit over SOC alone in patients with only-regional lymph node (M1a) or visceral metastases (M1c)? 2) Is bone metastasis count on bone scan predictive of benefit from prostate RT + SOC over SOC alone?
|
|
|
|
|
|
| Prevention and Treatment of Osteoporosis: What More do We Need to Know?
|
| Fred Saad, MD, FRCS
|
| Fred Saad spoke at the bone and bone metastases session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, discussing the prevention and treatment of osteoporosis. According to Dr. Saad, the risks and consequences of osteoporosis are well-established: among all men, there is a 4.6% life-time risk of hip fractures, 21.5% prevalence of vertebral fractures, and 31-38% mortality rate 1-year after a hip fracture. The impact of ADT on associated significant bone-loss is also well-established, with a 4.6% lumbar spine bone mineral density loss at one year of therapy.
|
|
|
|
|
|
| A Phase III Trial of Docetaxel versus Docetaxel and Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer: DORA
|
| Michael Morris, MD
|
| Michael Morris presented their phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA. Ra-223, a bone-targeted alpha therapy, is a well-tolerated treatment option that prolongs survival in patients with symptomatic mCRPC to bone. Docetaxel targets microtubule trafficking improving survival in the mCRPC and metastatic hormone-sensitive settings.
|
|
|
|
|
|
|
|
|
|
|
| Evaluating the Predictive Role of Automated Bone Scan Index in Selecting Newly Diagnosed Metastatic Prostate Cancer Patients for Prostate Radiotherapy: A STAMPEDE Trial Exploratory Analysis
|
| Syed Adnan Ali, MBBS
|
| Dr. Ali and colleagues presented results of their study evaluating in an exploratory fashion whether automated bone scan index can be used as a predictive imaging-based biomarker to define a metastatic hormone-naive prostate cancer population which would benefit from prostate radiotherapy.
|
|
|
|
|
|
| Decreased Fracture Rate by Mandating Bone-protecting Agents in the EORTC 1333/PEACE III Trial
|
| Bertrand F. Tombal, MD, PhD
|
| The question of whether mandated use of bone protecting agents, zoledronic acid or denosumab, would have mitigated the fracture risk and whether this risk also exists in the enzalutamide-radium-223 combination is presently unknown. At the ASCO 2019 prostate cancer session, Bertrand F. Tombal, MD, PhD, presented results of mandating bone protective agents for patients in the EORTC-1333-GUCG/PEACE III trial.
|
|
|
|
|
|
|
